Secondary HypogonadismPhase 3ZA-003ExtNCT01067365
Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism
A Phase 3 study testing Androxal in people with Secondary Hypogonadism, run by Repros Therapeutics Inc. at 18 sites in United States.
Trial summary
Subjects who completed ZA-003 were eligible to receive an additional year of treatment in this extension study. Read more about this study
- Who is it for?
- Ages 18 to 68 years, men only
- Conditions the study is for
- Secondary Hypogonadism
- What is being tested?
- Androxal
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 104 participants
- Where
- 18 sitesUnited States
- Study dates
- Mar 2006to May 2007
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 68 years
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Total serum testosterone concentrations < 300 ng/dL at baseline
Who cannot join
- Presence or history of prostate cancer
- Elevated PSA > 3.5 ng/mL
- Additional inclusion and exclusion criteria may apply.
Trial locations and contacts
18 sites in 1 country.
18 sites in 1 country
United States18 sites
The Center for Sexual Medicine at Sheppard Pratt
Baltimore, Maryland, 21285
Alabama Clinical Therapeutics, LLC
Birmingham, Alabama, 35235
Northern California Research Corp
Carmichael, California, 95608
Northeast Indiana Research, LLC
Fort Wayne, Indiana, 46825
Advanced Biomedical Research, Inc.
Hackensack, New Jersey, 07601
Medial Affiliated Research Center, Inc.
Huntsville, Alabama, 35801
Office of Michael Mall, MD
Las Vegas, Nevada, 89109
Office of Stephen Miller, MD
Las Vegas, Nevada, 89144
Office of Gary S. Karlin, MD
Lawrenceville, New Jersey, 08648
Office of Keith Pierce, MD
Livonia, Michigan, 48152
Commonweatlh Biomedical Research
Madisonville, Kentucky, 42431
Prime-Care Clinical Research
Mission Viejo, California, 92691
Medical Research Associates of Nashville
Nashville, Tennessee, 37203
Salt Lake Research
Salt Lake City, Utah, 84107
Urology San Antonio Research, PA
San Antonio, Texas, 78229
Southeastern Research Group, Inc.
Tallahassee, Florida, 32308
Harbor-UCLA Medical Center
Torrance, California, 90502
Chase Medical Research, LLC
Waterbury, Connecticut, 06708
About this study
Official title: An Open-Label, Multiple Center Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism Who Completed ZA-003
Subjects who completed ZA-003 were eligible to receive an additional year of treatment in this extension study.
Read the detailed description
The objectives of this study were to evaluate the safety and efficacy of Androxal® administered orally once daily for one year in men with secondary hypogonadism and who had completed ZA-003.
- Conditions
- Secondary Hypogonadism
- Being tested
- Androxal
- Keywords
- Secondary Hypogonadism
- Medical subject headings
- Hypogonadism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AndroxalDrug
Also called Enclomiphene citrate
12.5 mg once daily
AndroxalDrug
Also called Enclomiphene citrate
25 mg once daily
| Study group | Role | What they receive |
|---|---|---|
| 12.5 mg Androxal | Experimental | 12.5 mg Androxal daily Receives: Drug: Androxal |
| 25 mg Androxal | Experimental | 25 mg Androxal daily Receives: Drug: Androxal |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluate the safety of Androxal™ administered in men with secondary hypogonadism
Measured: One year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Feb 2010 (estimated)
- Study startMar 2006
- Primary completionMay 2007
- Study completionMay 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Secondary HypogonadismStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 104 participants (actual)
Sponsor and investigators
- Lead sponsor
- Repros Therapeutics Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Andre van As, MD, PhD, Study director, Repros Therapeutics Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01067365
- Sponsor's protocol ID
- ZA-003 Extension Study
- Acronym
- ZA-003Ext
- Status last verified
- Jun 2014
- First submitted
- 10 Feb 2010
- Last updated
- 27 Jun 2014
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Jun 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-Label, Multiple Center Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism Who Completed ZA-003
- ClinicalTrials.gov ID
- NCT01067365
- Acronym / sponsor ID
- ZA-003Ext / ZA-003 Extension Study
- Conditions
- Secondary Hypogonadism
- Keywords
- Secondary Hypogonadism
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 104 participants (actual)
- Lead sponsor
- Repros Therapeutics Inc.Industry (pharma, biotech, devices)
- Study start
- Mar 2006
- Primary completion
- May 2007 (actual)
- Study completion
- May 2007 (actual)
- First posted
- 11 Feb 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Subjects who completed ZA-003 were eligible to receive an additional year of treatment in this extension study.
Detailed description
The objectives of this study were to evaluate the safety and efficacy of Androxal® administered orally once daily for one year in men with secondary hypogonadism and who had completed ZA-003.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 12.5 mg Androxal | Experimental | Drug: Androxal12.5 mg Androxal daily |
| 25 mg Androxal | Experimental | Drug: Androxal25 mg Androxal daily |
Who may qualify
- Ages
- 18 to 68 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Total serum testosterone concentrations < 300 ng/dL at baseline
Key exclusion criteria (3 listed)
- Presence or history of prostate cancer
- Elevated PSA > 3.5 ng/mL
- Additional inclusion and exclusion criteria may apply.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AndroxalAlso: Enclomiphene citrate12.5 mg once daily | Drug | 12.5 mg Androxal |
| AndroxalAlso: Enclomiphene citrate25 mg once daily | Drug | 25 mg Androxal |
Primary outcome
Evaluate the safety of Androxal™ administered in men with secondary hypogonadism
Time frame: One year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jun 2014.
Related trials for Secondary Hypogonadism
RecruitingObservational study
Inherited Reproductive Disorders
Genetic Disorder, Infertility
Not yet recruitingPhase 3
SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years
Craniopharyngioma, Child
Enrolling by invitation
AIM-TEST: Microbiome-Targeted Nutrition for Functional Secondary Hypogonadism
Hypogonadism, Male, Secondary Hypogonadism
RecruitingPhase 2
Kisspeptin Administration Subcutaneously to Patients With IHH
Hypogonadotropic Hypogonadism
RecruitingPhase 2
Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea
Hypothalamic Amenorrhea, Hypogonadotropic Hypogonadism
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Andre van As, MD, PhD study director
Repros Therapeutics Inc.
18 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Androxal in people with Secondary Hypogonadism, run by Repros Therapeutics Inc. at 18 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Jun 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 18 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluate the safety of Androxal™ administered in men with secondary hypogonadism (time frame: One year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jun 2014.